Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on asymmetric synthesis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel patent CN105801572A offers safer chiral introduction and reduced environmental impact for scalable Rivaroxaban manufacturing supply chains.
Advanced synthesis of hexahydrofuro[2,3-b]furan-3-ol via patent CN103864813A. Offers cost reduction in API manufacturing and reliable supply chain for pharmaceutical intermediates.
Novel synthesis of binaphthyl NN-dioxide ligands via Pd-catalyzed carbonylation. High yield over 75 percent and purity exceeding 95 percent. Reliable supplier for asymmetric catalysis.
Patent CN101679295A discloses novel hydantoins for enantiomerically pure amino acids, enabling cost-effective Ramipril and Perindopril manufacturing.
Patent CN109776506B details a novel 10-step synthesis of chiral (-)-cephalotaxine from furan. Discover cost-effective manufacturing and supply chain advantages.
Patent CN111620860B reveals a streamlined synthesis for Afuresertib, eliminating complex protection steps for significant cost reduction and supply chain reliability in AKT inhibitor manufacturing.
Patent CN101875666B details a novel asymmetric synthesis for high-purity 1,3-alkamine compounds, offering significant cost reduction in API manufacturing and reliable supply chain solutions.
Patent CN109851634B discloses Yu-Phos ligands for asymmetric catalysis. Enables cost reduction in pharmaceutical intermediate manufacturing with high stereoselectivity.
Novel one-step synthesis of N,N-bis-[(R)-(2-methoxy-phenyl) cyanomethyl]-(S)-1-phenylethylamine using copper catalysis for high-purity pharmaceutical intermediates.
Patent CN108558715A details high-yield route. Reduces cost and environmental impact for pharmaceutical intermediates manufacturing significantly.
Novel patent CN108570014A details high-yield chiral morpholine synthesis. Offers cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN105646319B reveals a column-free synthesis route for Brivaracetam, enabling cost reduction in API manufacturing and high-purity output suitable for commercial scale-up.
Patent CN107417615A enables high-purity quinolinone manufacturing via visible light catalysis. Discover cost reduction and supply chain advantages for pharmaceutical intermediates.
Stable chiral intermediate synthesis via CN109851542A. Enhanced storage stability and cost reduction in pharmaceutical intermediate manufacturing for global supply chains.
Novel route for (S)-2-amino suberic acid esters using RuO4 oxidation and Wittig reaction, offering high optical purity and scalable manufacturing for pharmaceutical applications.
Discover the novel organocatalytic synthesis of chiral thiopyranoindolobenzothiophene sulfones. High stereoselectivity and mild conditions for efficient pharmaceutical intermediate manufacturing.
Novel epoxidation-ring opening route for antiviral intermediates. Reduces cost and improves purity compared to lithium aluminum hydride methods. Reliable supplier.
Patent CN102153557A reveals ethylenediamine-based NHC salts for chiral synthesis. Enables cost reduction in pharmaceutical intermediate manufacturing with scalable routes.
Patent CN101570550A details a scalable, chromatography-free route for chiral ferrocene ligands, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Novel patent CN111454217A details a green Rh-catalyzed route for Avapritinib intermediates, offering safer chiral induction and scalable manufacturing for global supply chains.